References
- Mirzoyev SA, Schrum AG, Davis MD, Torgerson RR. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009. J Investig Dermatol. 2014;134:1141–42.
- Messenger AG, McKillop J, Farrant P, et al. British Association of Dermatologists' guidelines for the management of alopecia areata 2012. Br J Dermatol. 2012;166:916–26.
- Shapiro J. Current treatment of alopecia areata. J Investig Dermatol Symp Proc. 2013;16:S42–S44.
- Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor Baricitinib. EBioMedicine. 2015;2:351–55.
- Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20:1043–49.
- Falto-Aizpurua L, Choudhary S, Tosti A. Emerging treatments in alopecia. Expert Opin Emerg Drugs. 2014;19:545–56.
- Kino T, Hatanaka H, Hashimoto M, et al. a novel immunosuppressant isolated from a streptomyces. I. Fermentation, isolation and physico-chemical and biological characteristics. J Antibiot. 1987;40:1249–55.
- Kino T, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot. 1987;40:1256–65.